Fiche centre
The Ottawa Hospital
Ottawa — Canada
Essais liés8clinical trials
VilleOttawalocalisation
PaysCanadalocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06570473
Essais cliniques associés
8| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| BI 690517 | Maladie rénale chronique | Phase 3 | NCT06531824 | EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | ACTIVE_NOT_RECRUITING |
| Empagliflozin | Insuffisance cardiaque | Phase 2 | NCT06570473 | CRAVE — Feasibility Trial for a Right Ventricular Failure Platform Trial | RECRUITING |
| Pitolisant Oral Tablet | Myopathies | Phase 2 | NCT04886518 | Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1 | COMPLETED |
| AOC 1001 (del-desiran) | Myopathies | Phase 3 | NCT06411288 | HARBOR — Global Study of Del-desiran for the Treatment of DM1 | COMPLETED |
| Hydroxychloroquine (HCQ) | Parkinson | Phase 2 | NCT06816810 | A Study to Evaluate Efficacy, Safety and Tolerability of Hydroxychloroquine in Subjects With Parkinson's Disease | ACTIVE_NOT_RECRUITING |
| Del-desiran (AOC 1001) | Myopathies | Phase 3 | NCT07008469 | HARBOR-OLE — Global Open-Label Extension Study of Del-desiran for the Treatment of DM1 | ENROLLING_BY_INVITATION |
| AOC-1020 | Myopathies | Phase 3 | NCT07038200 | FORTITUDE-3 — A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD | RECRUITING |
| The Ontario Neurodegenerative Disease Research Initiative | Sclérose latérale amyotrophique | À vérifier | NCT04104373 | The Ontario Neurodegenerative Disease Research Initiative | COMPLETED |